These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 9816022

  • 1. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
    Lister J, Rybka WB, Donnenberg AD, deMagalhaes-Silverman M, Pincus SM, Bloom EJ, Elder EM, Ball ED, Whiteside TL.
    Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
    [Abstract] [Full Text] [Related]

  • 2. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J, Burns LJ.
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [Abstract] [Full Text] [Related]

  • 3. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K, Margolin K, Champlin R, Forman S.
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [Abstract] [Full Text] [Related]

  • 4. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
    Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, Burger SR, Panoskaltsis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS.
    Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
    [Abstract] [Full Text] [Related]

  • 5. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A.
    Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
    [Abstract] [Full Text] [Related]

  • 6. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
    Bosly A, Guillaume T, Brice P, Humblet Y, Staquet P, Doyen C, Chatelain B, Franks CR, Gisselbrecht C, Symann M.
    Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
    [Abstract] [Full Text] [Related]

  • 7. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer.
    deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W, Whiteside T, Ball E.
    J Immunother; 2000 Jan; 23(1):154-60. PubMed ID: 10687148
    [Abstract] [Full Text] [Related]

  • 8. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR, Parreira A, Ascensão JL.
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [Abstract] [Full Text] [Related]

  • 9. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates.
    Meehan KR, Verma UN, Cahill R, Frankel S, Areman EM, Sacher RA, Foelber R, Rajagopal C, Gehan EA, Lippman ME, Mazumder A.
    Bone Marrow Transplant; 1997 Oct; 20(8):643-51. PubMed ID: 9383227
    [Abstract] [Full Text] [Related]

  • 10. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F, Pardo N, Peiró M, Bertran E, Amill B, García J, Cubells J, Rueda F.
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [Abstract] [Full Text] [Related]

  • 11. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study.
    Toh HC, McAfee SL, Sackstein R, Multani P, Cox BF, Garcia-Carbonero R, Colby C, Spitzer TR.
    Bone Marrow Transplant; 2000 Jan; 25(1):19-24. PubMed ID: 10654009
    [Abstract] [Full Text] [Related]

  • 12. Comparison of interleukin-12 with lung cancer and malignant lymphoma undergoing autologous peripheral blood stem cell transplantation.
    Yoshimura C, Nomura S, Kanazawa S, Kuwana M, Yamaguchi K, Fukuhara S.
    J Cancer Res Clin Oncol; 2002 Jan; 128(1):29-36. PubMed ID: 11862469
    [Abstract] [Full Text] [Related]

  • 13. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, Ritz J.
    Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
    [Abstract] [Full Text] [Related]

  • 14. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer.
    Perillo A, Pierelli L, Battaglia A, Salerno MG, Rutella S, Cortesi E, Fattorossi A, De Rosa L, Ferraù F, Lalle M, Leone G, Mancuso S, Scambia G.
    Bone Marrow Transplant; 2002 Nov; 30(9):571-8. PubMed ID: 12407431
    [Abstract] [Full Text] [Related]

  • 15. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG.
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [Abstract] [Full Text] [Related]

  • 16. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S, Pennel N, Reis M, Pinkerton P, Dubé I, Hewitt K, Berinstein NL.
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [Abstract] [Full Text] [Related]

  • 17. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.
    Cowan KH, Moscow JA, Huang H, Zujewski JA, O'Shaughnessy J, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinberg S, Wilson W, Goldspiel B, Read EJ, Leitman SF, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis A.
    Clin Cancer Res; 1999 Jul; 5(7):1619-28. PubMed ID: 10430060
    [Abstract] [Full Text] [Related]

  • 18. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 19. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
    Porrata LF, Inwards DJ, Lacy MQ, Markovic SN.
    Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
    [Abstract] [Full Text] [Related]

  • 20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.